$PMVP News

Last published 3d ago

3d agoPMVPPMV Pharmaceuticals, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1w agoPMVPPivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026GlobeNewswirePRINCETON, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of
1mo agoPMVPEarnings Call - PMV PHARMACEUTICALS INCEarnings Call TranscriptsSo my name is Masha Poyorovsky. I am a scientist at P&V Pharmaceuticals. We are a company that's developing Rosetta POP for the treatment of women with platinum resistant refractory ovarian cancer. So I have dedicated my
2mo agoPMVPPMV Pharmaceuticals Appoints Philip Herman as Chief Commercial OfficerGlobeNewswireCommercial leadership appointment supports launch preparation for rezatapopt Company planning NDA submission for accelerated approval of rezatapopt in patients with platinum-resistant/refractory ovarian cancer in
2mo agoPMVPPMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of SecuritiesGlobeNewswirePRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of
2mo agoPMVPPMV Pharma Announces Proposed Public Offering of SecuritiesGlobeNewswirePRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of
2mo agoPMVPPMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal TrialGlobeNewswire46% ORR observed among 76 evaluable patients in the ovarian cancer cohort with a median duration of response of 10.0 monthsRecent FDA interaction supports NDA submission strategy for accelerated approval of rezatapopt
3mo agoPMVPPMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate HighlightsGlobeNewswireEnrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completedRezatapopt NDA submission for
6mo agoPMVPPMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate HighlightsGlobeNewswireRezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancerNew England Journal of Medicine published first-in-human rezatapopt data showing
6mo agoPMVPPMV Pharmaceuticals Announces Board Chair TransitionGlobeNewswirePRINCETON, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule
8mo agoPMVPPMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate HighlightsGlobeNewswireEnrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutationRezatapopt granted Orphan
8mo agoPMVPNew England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid TumorsGlobeNewswirePRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule
1y agoPMVPPMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate HighlightsGlobeNewswireUpdated clinical results from Phase 2 pivotal portion of the PYNNACLE study evaluating rezatapopt featured in late-breaking oral presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and
1y agoPMVPPMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C MutationGlobeNewswireData presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ovarian, lung, breast,
1y agoPMVPPMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewswireOral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors harboring a TP53 Y220C
1y agoPMVPPMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C MutationGlobeNewswirePYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary
1y agoPMVPPMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate HighlightsGlobeNewswirePMV will host an investor webinar on Wednesday, September 10, 2025 at 8:00 AM ET to review Phase 2 PYNNACLE clinical trial interim analysis Interim analysis will include data for approximately 65 patients with at least
1y agoPMVPPMV Pharmaceuticals to Participate at Upcoming Investor ConferencesGlobeNewswirePRINCETON, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic
1y agoPMVPPMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate HighlightsGlobeNewswireEnrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumorsInterim analysis from Phase 2 PYNNACLE
1y agoPMVPPMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate HighlightsGlobeNewswireEnrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 90% of sites activated across
1y agoPMVPPMV Pharmaceuticals to Participate at Upcoming Investor ConferencesGlobeNewswirePRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting
2y agoPMVPPMV Pharmaceuticals Reports Third Quarter 2024 Financial ResultsGlobeNewswireEnrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 75% of sites activated across the
2y agoPMVPPMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical TrialGlobeNewswireEnrollment on track in registrational Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 75% of sites activated
2y agoPMVPPMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical TrialGlobeNewswireEnrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 60% of sites activated across the
2y agoPMVPPMV Pharmaceuticals to Participate at Upcoming Investor Conferences in JuneGlobeNewswirePRINCETON, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting
2y agoPMVPFoundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C ReactivatorGlobeNewswireBOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ:PMVP, "PMV Pharma")) today announced a partnership to develop Foundation Medicine's
2y agoPMVPFoundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C ReactivatorBusiness WireFoundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ:PMVP, "PMV Pharma")) today announced a partnership to develop Foundation Medicine's tissue-based comprehensive genomic profiling test,
2y agoPMVPPMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate HighlightsGlobeNewswireFirst patient dosed and continued enrollment in Phase 2 portion of the PYNNACLE trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors Phase 1 data of
2y agoPMVPPMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid TumorsGlobeNewswireRezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type (WT)First patient dosed in Phase 2 portion of the PYNNACLE
2y agoPMVPPMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's CancerGlobeNewswirePhase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation featured in a
2y agoPMVPPMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate HighlightsGlobeNewswireRegistrational, tumor-agnostic Phase 2 portion of PYNNACLE clinical trial of rezatapopt (PC14586), a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a TP53 Y220C
2y agoPMVPPMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care ConferenceGlobeNewswirePRINCETON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting
2y agoPMVPPMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash RunwayGlobeNewswirePrioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of approximately 30%Unaudited cash, cash equivalents, and marketable securities totaling approximately $229
2y agoPMVPPMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage DevelopmentGlobeNewswirePC14586 clinical program to be led by Deepika Jalota, Pharm.D. (Chief Development Officer) and Marc Fellous, M.D. (Senior Vice President, Head of Clinical Development and Medical Affairs)Michael Carulli promoted to Chief
3y agoPMVPPMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate HighlightsGlobeNewswireUpdated data from Phase 1 PYNNACLE clinical trial of PC14586 presented at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrated responses across multiple tumor types with
3y agoPMVPPMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C MutationGlobeNewswireUpdated PC14586 Phase 1 data presented today as a late-breaking poster at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsConfirmed responses observed in multiple tumor types
3y agoPMVPPMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL WebinarGlobeNewswirePRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting
3y agoPMVPPMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewswireLate-breaking poster presentation to highlight updated Phase 1 clinical data of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have a TP53 Y220C
3y agoPMVPPMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare ConferenceGlobeNewswirePRINCETON, N.J., June 06, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting
3y agoPMVPPMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate HighlightsGlobeNewswireContinued progress in the ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; next update is expected
3y agoPMVPPMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate HighlightsGlobeNewswireContinued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; PMV expects to provide next
3y agoPMVPPMV Pharmaceuticals to Participate at Upcoming Investor Conferences in MarchGlobeNewswirePRINCETON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP, "PMV Pharma")), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic
3y agoPMVPPMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx ConferenceGlobeNewswireCRANBURY, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP, "PMV Pharma")), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic
4y agoPMVPPMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate HighlightsGlobeNewswireEnrollment continued in the Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation Phase 1b combination
4y agoPMVPPMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of DirectorsGlobeNewswireCRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting
4y agoPMVPPMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate HighlightsGlobeNewswireInitial PC14586 Phase 1 data presented at the American Society of Clinical Oncology Annual Meeting (ASCO) demonstrated responses in patients across multiple solid tumor types with a p53 Y220C mutation Entered into a clinical collaboration with Merck to
4y agoPMVPPMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid TumorsGlobeNewswireCRANBURY, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP, "PMV Pharma"))), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced
4y agoPMVPPMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare ConferenceGlobeNewswireCRANBURY, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP, "PMV Pharma"))), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced
4y agoPMVPPMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C MutationGlobeNewswireOverall response rate (ORR) of 32% (8/25) achieved in higher dose cohorts per RECIST v1.1 Partial responses observed across six distinct tumor types Data featured as an oral presentation at ASCO; Company to host investor event via webcast today at
4y agoPMVPPMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswirePreliminary results represent the first clinical evidence of targeting a p53 Y220C mutation ASCO abstract highlights 3/10 (30%) partial responses in patients treated in higher dose cohorts and activity observed in multiple tumor types Updated data fr